secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001842952-24-000083
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M
--------------------------------------------------------------------------------

- $15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.
- CT-202 (formerly BA3362) IND filing expected mid-2026; Context to fund all development.
- Cash runway into 2027 covering CTIM-76 and CT-95 Phase 1 trials plus CT-202 IND expenses.
- First CTIM-76 patient dosing expected Oct/Nov 2024; initial dose escalation data 1H 2026.
- CT-95 Phase 1 initial dose escalation data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000083/0001842952-24-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000083/cntx-20240923.htm
  HTML page:      https://secwatch.observer/filing/0001842952-24-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer